← Back to Clinical Trials
Recruiting NCT07662837

NCT07662837 Effects of Tai Chi Therapy Versus Qi-Gong in Stage-I Parkinson's Patients.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07662837
Status Recruiting
Phase
Sponsor Lahore University of Biological and Applied Sciences
Condition PARKINSON DISEASE (Disorder)
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-05-30
Primary Completion 2026-08-30

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Tai ChiQi Gong

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-05-30 with a primary completion date of 2026-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study has important clinical, academic, and practical relevance in neuromuscular rehabilitation. Clinically, it aims to identify effective and tolerable rehabilitation strategies for individuals with Parkinson's disease by comparing Tai Chi Therapy with Qi-Gong there by supporting evidence-based physiotherapy practice and improving patient adherence. Academically, it contributes to the limited literature on comparative effectiveness of these interventions and incorporates patient-centered outcomes such as exercise perception, which are often underreported. From a practical and societal perspective, identifying a more acceptable and effective approach may enhance long-term participation in rehabilitation, potentially slow disease progression, and reduce the overall healthcare burden associated with Parkinson's disease.

Eligibility Criteria

Inclusion Criteria: Diagnosis of PD based on the Hoehn \& Yahr staging system (Stages I). Male or female patients aged between 50-65 years. Currently receiving stable anti-Parkinsonian medication, with no changes in the treatment regimen for at least 3 months. Basic self-care ability with no severe cognitive impairment (Mini-Mental State Examination \[MMSE\] score ≥24). Exclusion Criteria: Depression, as assessed based on a score of \>16 for the Beck Depression Inventory-II (BDI-II). Recent deep brain stimulation (DBS) treatment. Use of medication that interferes with cognition, alertness, or attention. Current participation in an exercise training program.

Contact & Investigator

Central Contact

Maryam Fayyaz

✉ maryamfayyazawan@gmail.com

📞 03374677916

Principal Investigator

Salwa Atta

STUDY DIRECTOR

Lahore University of Biological & Applied Sciences

Frequently Asked Questions

Who can join the NCT07662837 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 65 Years, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07662837 currently recruiting?

Yes, NCT07662837 is actively recruiting participants. Contact the research team at maryamfayyazawan@gmail.com for enrollment information.

Where is the NCT07662837 trial being conducted?

This trial is being conducted at Lahore, Pakistan, Lahore, Pakistan.

Who is sponsoring the NCT07662837 clinical trial?

NCT07662837 is sponsored by Lahore University of Biological and Applied Sciences. The principal investigator is Salwa Atta at Lahore University of Biological & Applied Sciences. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology